Brokerages Expect Agenus Inc. (NASDAQ:AGEN) Will Post Earnings of -$0.36 Per Share
Wall Street brokerages forecast that Agenus Inc. (NASDAQ:AGEN) will announce earnings per share (EPS) of ($0.36) for the current quarter, Zacks reports. Two analysts have made estimates for Agenus’ earnings. The lowest EPS estimate is ($0.37) and the highest is ($0.34). Agenus reported earnings of ($0.24) per share during the same quarter last year, which would indicate a negative year over year growth rate of 50%. The firm is expected to announce its next earnings results on Thursday, July 27th.
According to Zacks, analysts expect that Agenus will report full-year earnings of ($1.14) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($1.37) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Agenus.
Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.14. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 257.79%. The company had revenue of $26.96 million during the quarter, compared to the consensus estimate of $5.22 million.
Several research analysts recently issued reports on AGEN shares. Maxim Group reissued a “buy” rating and issued a $7.00 price target on shares of Agenus in a research report on Sunday, April 23rd. Zacks Investment Research raised shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price target for the company in a research report on Wednesday, July 5th. ValuEngine lowered shares of Agenus from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th. Finally, HC Wainwright set a $5.00 price target on shares of Agenus and gave the stock a “hold” rating in a research report on Saturday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Agenus currently has an average rating of “Buy” and a consensus target price of $5.88.
Shares of Agenus (NASDAQ:AGEN) traded up 2.77% during trading on Monday, reaching $5.19. The company’s stock had a trading volume of 826,750 shares. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49. The company’s 50-day moving average price is $3.94 and its 200 day moving average price is $3.87. The stock’s market capitalization is $514.42 million.
COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Agenus Inc. (NASDAQ:AGEN) Will Post Earnings of -$0.36 Per Share” was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/24/brokerages-expect-agenus-inc-nasdaqagen-will-post-earnings-of-0-36-per-share.html.
Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its stake in Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 23,689 shares during the period. AQR Capital Management LLC acquired a new position in shares of Agenus during the fourth quarter worth about $143,000. American International Group Inc. boosted its position in shares of Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,984 shares during the last quarter. Quotient Investors LLC boosted its position in shares of Agenus by 8.8% in the first quarter. Quotient Investors LLC now owns 47,000 shares of the biotechnology company’s stock worth $177,000 after buying an additional 3,800 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Agenus by 203.7% in the first quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock worth $196,000 after buying an additional 34,833 shares during the last quarter. 42.61% of the stock is currently owned by institutional investors and hedge funds.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.